Angioedema ||| S:0 E:10 ||| NNP
:  ||| S:10 E:12 ||| :
differential  ||| S:12 E:25 ||| JJ
diagnosis  ||| S:25 E:35 ||| NN
and  ||| S:35 E:39 ||| CC
treatment  ||| S:39 E:49 ||| NN
Conditions  ||| S:49 E:60 ||| NNS
causing  ||| S:60 E:68 ||| VBG
angioedema  ||| S:68 E:79 ||| NNS
can  ||| S:79 E:83 ||| MD
be  ||| S:83 E:86 ||| VB
loosely  ||| S:86 E:94 ||| RB
classified  ||| S:94 E:105 ||| VBN
as  ||| S:105 E:108 ||| IN
those  ||| S:108 E:114 ||| DT
with  ||| S:114 E:119 ||| IN
underlying  ||| S:119 E:130 ||| VBG
C1-inhibitor  ||| S:130 E:143 ||| CD
deficiency  ||| S:143 E:154 ||| NN
or  ||| S:154 E:157 ||| CC
dysfunction  ||| S:157 E:169 ||| NNS
and  ||| S:169 E:173 ||| CC
those  ||| S:173 E:179 ||| DT
that  ||| S:179 E:184 ||| WDT
do  ||| S:184 E:187 ||| VBP
not ||| S:187 E:190 ||| RB
.  ||| S:190 E:192 ||| .
Determining  ||| S:192 E:204 ||| VBG
the  ||| S:204 E:208 ||| DT
root  ||| S:208 E:213 ||| NN
cause  ||| S:213 E:219 ||| NN
of  ||| S:219 E:222 ||| IN
symptoms  ||| S:222 E:231 ||| NNS
and  ||| S:231 E:235 ||| CC
ruling  ||| S:235 E:242 ||| VBG
out  ||| S:242 E:246 ||| RP
conditions  ||| S:246 E:257 ||| NNS
that  ||| S:257 E:262 ||| IN
masquerade  ||| S:262 E:273 ||| NN
as  ||| S:273 E:276 ||| IN
angioedema  ||| S:276 E:287 ||| JJ
help  ||| S:287 E:292 ||| NN
clinicians  ||| S:292 E:303 ||| NNS
plan  ||| S:303 E:308 ||| VBP
appropriate  ||| S:308 E:320 ||| JJ
management ||| S:320 E:330 ||| NN
.  ||| S:330 E:332 ||| .
The  ||| S:332 E:336 ||| DT
various  ||| S:336 E:344 ||| JJ
etiologies  ||| S:344 E:355 ||| NN
of  ||| S:355 E:358 ||| IN
angioedema  ||| S:358 E:369 ||| NNS
have  ||| S:369 E:374 ||| VBP
overlapping  ||| S:374 E:386 ||| VBG
symptoms  ||| S:386 E:395 ||| NNS
that  ||| S:395 E:400 ||| WDT
can  ||| S:400 E:404 ||| MD
complicate  ||| S:404 E:415 ||| VB
the  ||| S:415 E:419 ||| DT
diagnosis ||| S:419 E:428 ||| NN
.  ||| S:428 E:430 ||| .
An  ||| S:430 E:433 ||| DT
awareness  ||| S:433 E:443 ||| NN
of  ||| S:443 E:446 ||| IN
features  ||| S:446 E:455 ||| NNS
unique  ||| S:455 E:462 ||| JJ
to  ||| S:462 E:465 ||| TO
a  ||| S:465 E:467 ||| DT
specific  ||| S:467 E:476 ||| JJ
cause  ||| S:476 E:482 ||| NN
of  ||| S:482 E:485 ||| IN
angioedema  ||| S:485 E:496 ||| NNS
will  ||| S:496 E:501 ||| MD
aid  ||| S:501 E:505 ||| VB
in  ||| S:505 E:508 ||| IN
the  ||| S:508 E:512 ||| DT
differential  ||| S:512 E:525 ||| JJ
diagnosis ||| S:525 E:534 ||| NN
.  ||| S:534 E:536 ||| .
A  ||| S:536 E:538 ||| DT
thorough  ||| S:538 E:547 ||| JJ
history  ||| S:547 E:555 ||| NN
may  ||| S:555 E:559 ||| MD
reveal  ||| S:559 E:566 ||| VB
a  ||| S:566 E:568 ||| DT
family  ||| S:568 E:575 ||| NN
history  ||| S:575 E:583 ||| NN
of  ||| S:583 E:586 ||| IN
episodic  ||| S:586 E:595 ||| JJ
swelling ||| S:595 E:603 ||| NN
,  ||| S:603 E:605 ||| ,
bouts  ||| S:605 E:611 ||| NNS
of  ||| S:611 E:614 ||| IN
swelling  ||| S:614 E:623 ||| VBG
associated  ||| S:623 E:634 ||| VBN
with  ||| S:634 E:639 ||| IN
medication  ||| S:639 E:650 ||| NN
use ||| S:650 E:653 ||| NN
,  ||| S:653 E:655 ||| ,
or  ||| S:655 E:658 ||| CC
swelling  ||| S:658 E:667 ||| VBG
associated  ||| S:667 E:678 ||| VBN
with  ||| S:678 E:683 ||| IN
certain  ||| S:683 E:691 ||| JJ
foods  ||| S:691 E:697 ||| NNS
or  ||| S:697 E:700 ||| CC
environmental  ||| S:700 E:714 ||| JJ
allergens ||| S:714 E:723 ||| NN
.  ||| S:723 E:725 ||| .
Similarly ||| S:725 E:734 ||| RB
,  ||| S:734 E:736 ||| ,
a  ||| S:736 E:738 ||| DT
history  ||| S:738 E:746 ||| NN
of  ||| S:746 E:749 ||| IN
symptom  ||| S:749 E:757 ||| JJ
onset  ||| S:757 E:763 ||| NN
later  ||| S:763 E:769 ||| RBR
in  ||| S:769 E:772 ||| IN
life  ||| S:772 E:777 ||| NN
is  ||| S:777 E:780 ||| VBZ
more  ||| S:780 E:785 ||| RBR
common  ||| S:785 E:792 ||| JJ
in  ||| S:792 E:795 ||| IN
acquired  ||| S:795 E:804 ||| JJ
angioedema ||| S:804 E:814 ||| NN
.  ||| S:814 E:816 ||| .
The  ||| S:816 E:820 ||| DT
presence  ||| S:820 E:829 ||| NN
of  ||| S:829 E:832 ||| IN
urticaria  ||| S:832 E:842 ||| NN
suggests  ||| S:842 E:851 ||| VBZ
an  ||| S:851 E:854 ||| DT
allergic  ||| S:854 E:863 ||| JJ
component ||| S:863 E:872 ||| NN
.  ||| S:872 E:874 ||| .
Treatment  ||| S:874 E:884 ||| NN
strategies  ||| S:884 E:895 ||| NNS
have  ||| S:895 E:900 ||| VBP
been  ||| S:900 E:905 ||| VBN
devised  ||| S:905 E:913 ||| VBN
for  ||| S:913 E:917 ||| IN
all  ||| S:917 E:921 ||| DT
forms  ||| S:921 E:927 ||| NNS
of  ||| S:927 E:930 ||| IN
angioedema ||| S:930 E:940 ||| NN
,  ||| S:940 E:942 ||| ,
although  ||| S:942 E:951 ||| IN
specific  ||| S:951 E:960 ||| JJ
therapeutic  ||| S:960 E:972 ||| JJ
targets  ||| S:972 E:980 ||| NNS
may  ||| S:980 E:984 ||| MD
be  ||| S:984 E:987 ||| VB
unknown ||| S:987 E:994 ||| JJ
.  ||| S:994 E:996 ||| .
Several  ||| S:996 E:1004 ||| JJ
medications  ||| S:1004 E:1016 ||| NNS
directed  ||| S:1016 E:1025 ||| VBN
at  ||| S:1025 E:1028 ||| IN
the  ||| S:1028 E:1032 ||| DT
underlying  ||| S:1032 E:1043 ||| JJ
cause  ||| S:1043 E:1049 ||| NN
of  ||| S:1049 E:1052 ||| IN
symptoms  ||| S:1052 E:1061 ||| NNS
in  ||| S:1061 E:1064 ||| IN
hereditary  ||| S:1064 E:1075 ||| JJ
angioedema  ||| S:1075 E:1086 ||| NNS
have  ||| S:1086 E:1091 ||| VBP
been  ||| S:1091 E:1096 ||| VBN
recently  ||| S:1096 E:1105 ||| RB
approved  ||| S:1105 E:1114 ||| VBN
for  ||| S:1114 E:1118 ||| IN
use  ||| S:1118 E:1122 ||| NN
in  ||| S:1122 E:1125 ||| IN
the  ||| S:1125 E:1129 ||| DT
United  ||| S:1129 E:1136 ||| NNP
States ||| S:1136 E:1142 ||| NNPS
.  ||| S:1142 E:1144 ||| .
Clinical  ||| S:1144 E:1153 ||| JJ
symptoms ||| S:1153 E:1161 ||| NNS
,  ||| S:1161 E:1163 ||| ,
differential  ||| S:1163 E:1176 ||| JJ
diagnosis ||| S:1176 E:1185 ||| NN
,  ||| S:1185 E:1187 ||| ,
and  ||| S:1187 E:1191 ||| CC
management  ||| S:1191 E:1202 ||| NN
strategies  ||| S:1202 E:1213 ||| NNS
for  ||| S:1213 E:1217 ||| IN
angioedema  ||| S:1217 E:1228 ||| NNS
are  ||| S:1228 E:1232 ||| VBP
reviewed  ||| S:1232 E:1241 ||| VBN
in  ||| S:1241 E:1244 ||| IN
this  ||| S:1244 E:1249 ||| DT
article ||| S:1249 E:1256 ||| NN
.  ||| S:1256 E:1258 ||| .
